What Happened

L’Oréal’s corporate venture capital fund BOLD invested $71M in Olix Pharmaceuticals, a South Korean biotech company specializing in RNAi therapeutics. The funding will advance Olix’s Small Interfering RNAi-based (siRNA) projects, particularly in skin and hair-related treatments.

Who Is Affected

Olix Pharmaceuticals will use the funds to accelerate its therapeutic projects. L’Oréal aims to strengthen its scientific partnership with Olix, leveraging its siRNA platform for beauty innovation. Weiss Asset Management also participated in the funding round.

Market Impact

• Increased focus on RNAi therapeutics in the beauty and biotech sectors.
• Potential for new partnerships in skin and hair-related treatments.
• Enhanced credibility for Olix Pharmaceuticals as a leader in siRNA technology.

What to Watch

Monitor Olix’s progress in advancing its siRNA projects and L’Oréal’s integration of RNAi technology into its beauty products. Watch for further investments or partnerships in the biotech space.